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Summary 
To study the role of the CD40-CD40 ligand interaction in the development of memory B cells 
and its level of action during primary antibody responses in vivo,  mice were injected with a 
soluble CD40 fusion protein (sCD40-%,I), so as to block the interaction. The effects of the treatment 
on the primary antibody response were reminiscent of hyper-immunoglobulin M (IgM) syndrome 
(HIMG1): antigen-specific IgG responses were grossly inhibited whereas the IgM response was 
augmented severalfold.  The latter  observation  suggests  that  there is  a  T-dependent,  CD40 
ligand-independent pathway of B cell activation that leads to IgM responses and that a significant 
component of the IgM in HIMG1 patients is derived from T-dependent responses. The secondary 
response was not readily blocked by sCD40-3'I  treatment, indicating a relative independence 
of CD40 ligation of antigen-experienced B cells. The most striking finding from these studies 
is that the development of memory B cell populations (measured by adoptive transfer) is grossly 
impaired by administration of sCD40-3'I  during the early induction phase of the response. It 
is surprising that although the generation memory is diminished, there is no quantitative difference 
in the development of germinal centers. Whereas entry of B cells into the memory cell pathway 
is dependent on CD40 ligation, the clonal expansion of the potential memory precursors in germinal 
centers seems not to require a CD40  signal. 
T 
he encounter of resting B cells with thymus-dependent 
antigens neither causes them to enter cell cycle nor to 
become responsive to lymphokines. For the induction of re- 
sponses to these very common antigens (virtually all protein 
antigens), B cells require additional stimuli to those received 
via slg if they are to accept the differentiation signals deliv- 
ered by T cell-derived lymphokines. In the mid-1980s it be- 
came clear that the source of these "accessory" or "costimula- 
tory" signals  was membrane-bound molecules on activated 
T cells. This was demonstrated first by using fixed, activated 
T  cells in coculture with B ceils (1,  2)  and subsequently, 
purified cell membranes from such cells (3-5). More recently, 
several laboratories have demonstrated that CD40 is among 
the most important B cell acceptor molecules acting during 
this interaction.  Genetically engineered, soluble forms of CD40 
largely block the B cell proliferation induced by fixed, acti- 
vated T  cells  (6-8). 
CD40 is expressed ubiquitously throughout the B cell lin- 
eage (9), as well as on interdigitating dendritic cells and on 
some epithelial cells (10).  It is grouped, on the basis of se- 
quence and structural homology, in the nerve growth factor 
family of receptors, which also includes TNF-ot receptor (11), 
CD27 (12), CD30 (13), and the Fas antigen (14). Antibodies 
to CD40 have been shown to be directly mitogenic for B 
cells,  and when immobilized on the surface of Fc recep- 
tor-bearing fibroblasts,  will support the long-term growth 
of nontransformed B cell lines (15). The growth-mediating 
effects of anti-CD40 are enhanced in the presence of other 
cofactors (e.g., IL-4 and anti-Ig;  16-18).  In particular,  the 
addition of lymphokines to these cultures induces differenti- 
ation, isotype switching, and antibody secretion (19-21). The 
molecular cloning  of the physiological ligand  for  CD40 
(22-24) showed it to be a type II membrane molecule, with 
homology to TNF (ol and/3), that is expressed after activa- 
tion of almost all CD4 § T  cells and a minority population 
of CD8 §  T  cells (25). 
Confirmation that interaction between CD40 and its ligand 
was pivotal in T-dependent B cell antibody responses came 
last year with a number of groups demonstrating mutations 
in the CD40-1igand (CD40-L) l gene as the molecular basis 
I Abbreviations used in this paper: CD40-L, CD40-1igand; GC, germinal 
center; HIMG1, X-linked  immunodeficiency  with hyper-lgM;  PNA, peanut 
agglutiniu; TD, thymus dependent; sCD40-yl, soluble mouse CD40- 
human Fc3,1 fusion protein. 
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munodeficiency condition known as Hyper-IgM Syndrome 
(HIMG1) (26-29).  Patients with this disease, among other 
problems, exhibit almost no serum Ig of the "switched" classes 
(i.e., IgG, A, or E), but have elevated levels of IgM and some- 
times IgD. It is a matter of contention whether the serum 
IgM in HIGM1 patients is made up of natural antibodies 
(derived from CD5 B cells [30])  or results from responses 
to thymus-independent antigens. A component may be thymus 
dependent (TD), as patients are reported to respond after pri- 
mary immunization with TD  antigens, albeit only in the 
IgM class (21, 31). It would seem, therefore, that T-dependent, 
antigen-specific IgM responses  can occur in the absence of 
CD40 ligation. This conclusion is challenged by data reported 
by Korth~iuer et al. (26):  B cells from HIMG1 patients fail 
to produce IgM after polyclonal stimulation with PWM un- 
less antibodies to CD40  are added to the culture. This in 
turn contradicts a number of previous studies that show no 
defect in PWM-stimulated IgM production by HIGM1 B 
cells (32-34),  even though it is known to be T  dependent 
in nature (35). Whichever of these results is correct, the cur- 
rent wisdom is that signals received through CD40 are cru- 
cial for the development of T-dependent antibody responses. 
In addition to its roles  in B cell  activation and isotype 
switching discussed above, antibodies to CD40 deliver very 
potent rescue/survival  signals to germinal center (GC) B cells 
that are susceptible  to apoptosis (36). As part of the process 
of B cell memory generation, B cells proliferate and somati- 
cally mutate in GC (37, 38). During this period they are ex- 
quisitely sensitive  to apoptosis,  in all likelihood because  of 
a loss ofbcl-2 expression (39). Rescue with antigen, although 
an important first step in the selection of high affinity mu- 
tants, is a much less potent survival  signal than ligation of 
CD40 (36). The cellular product of the CD40 rescue, in vitro, 
is a small, nondividing lymphocyte. This has led to the specu- 
lation that the CD40 signal, presumably in the absence of 
lymphokines, drives B cells into the memory pathway. The 
information available from HIMG1 patients is not conclu- 
sive concerning the generation of memory in the absence of 
CD40 ligation. Booster injections of vaccines continue to elicit 
IgM responses,  with only a few cases yielding IgG (31), but 
there has been little investigation of whether this represents 
a memory response. 
A lack of direct evidence concerning the role of CD40 li- 
gation in the development of B cell memory and a wish to 
learn about the exact level of action of CD40-L in vivo, given 
the many diverse functions assigned to it, led us to try to 
block the CD40-CD40 ligand interaction by injecting mice 
with a soluble form of mouse CD40 (a chimeric molecule 
with human Fc3'1) during immune responses.  We felt that 
such an approach would extend the knowledge derived from 
HIMG1, in that we could confine the blockade of CD40-L 
to defined periods of the immune response and so avoid any 
gross defects arising out of long-term inactivation of a multi- 
functional receptor.  The experiments highlight an important 
role for CD40 ligation in the differentiation to memory B 
cells but suggest this is separate from the initiation of clonal 
expansion of memory precursors in GC. 
Materials and Methods 
Construction of Soluble Mouse CD40-Human  IgGl Chimeric Pro- 
tein.  The primers used to amplify the extracellular portions of 
the  mouse  CD40  gene  (40) were 5'(GACTGAGCTCACCAT- 
GGTGTCTTTGCCTCGGCTGTG)  and  Y(TATACTTACCCA- 
TCCGGGACTTTAAACCACAG). cDNA  was  prepared from 
mouse splenic B cells (reagents purchased from Promega Corp., 
Madison, WI) and used as a template for PCR amplification.  Each 
primer contained restriction sites that enabled subcloning into the 
human IgG1 expression vector (7), together with a 3' splice donor 
site in the 3' primer to facilitate correct splicing to the human 3'1 
exons. The resulting plasmid was used to transform K803 bacteria. 
Transfection and Purification.  J558L plasmacytoma cells were 
transfected with the mCD40-hu3"l plasmid by protoplast fusion. 
Cells were plated in flat-bottomed 96-well plates at 5  x  104/ml 
in  IMDM  plus 10%  FCS  plus 10  /~g/ml mycophenolic acid 
(Calbiochem-Novabiochem Corp., La Jolla, CA) plus 250 #g/ml 
xanthine (Sigma Chemical Co., St. Louis, MO).  Clones arising 
around 2 wk later, after several renewals of selective media, were 
screened for the production of human IgG1 in the supernatants. 
Soluble mouse CD40-huyl was purified from large volumes  of  cul- 
ture  supernatants, after ammonium  sulphate precipitation, by 
binding to protein A columns (Pharmacia, Uppsala, Sweden) and 
elution at pH 3.5. 
T-dependent  B  Cell  Proliferation Assay.  The  I-Ad-restricted 
sperm whale myoglobin-specific  Thl clone, 11.3.7 (kindly provided 
by Dr. Alexandra Livingstone, Basel Institute for Immunology, 
Basel, Switzerland) was taken in a "resting" state (2 wk after its 
last antigenic stimulation) and activated for 18 h with 10 ng/ml 
PMA and 1 #g/ml ionomycin. Cells were washed and then fixed 
in 0.8% paraformaldehyde  as previously  described  (1). These fixed, 
activated T cells were placed in flat-bottomed 96-well plates at 10  s 
per well together with 105 high density DBA/2  splenic B cells 
taken from the 1.085-1.092-density interface of a Percoll gradient. 
These B cells had been extensively  depleted oft cells using a cock- 
tail of IgM antibodies to CD4, CDS, and Thyl plus rabbit com- 
plement followed by IgG antibodies to the same antigens coated 
onto Dynabeads (Dynal, Oslo). In some wells, anti-Ig antibodies 
(monoclonal anti-g; 187.1) or supernatant containing II,-4 (41) was 
added at 10/~g/ml and 1%, respectively. Cultures in IMDM plus 
10% FCS plus 2 mM t-glutamine plus 100 U/ml penicillin plus 
100 #g/ml plus 50 #M 2-ME, were continued for 66 h with 
[3H]thymidine (2  /zCi/well) added for the final 18  h.  Soluble 
mCD40-hu3"l was added to cultures at concentrations  varying  from 
0.1 to 10 #g/ml; maximal inhibition was observed at 2.5 #g/ml. 
In  Vivo Administration of Soluble CD40-hu'yL  Mice  were im- 
munized intraperitoneally  with 50 #g of alum-precipitated  antigen 
(except C5, see below, of which 10 #g was injected). Groups of 
five or six immunized mice were injected intravenously  either with 
sCD40-3~I or with purified human IgG1 myeloma protein (The 
Binding Site, Birmingham, UK) at 100/~g/mouse/d. The injec- 
tion of these substances was continued for 5 d or 10 d, or in some 
cases the onset delayed until day 4 after immunization and con- 
tinued for an additional 4 d. The antigens used in these studies 
were dinitrophenylated OVA, DNP-KLH (Calbiochem-Novabio- 
chem Corp.), native KLH, and the mouse complement compo- 
nent C5 (a gift from Dr. Brigitta Stockinger, National Institute 
for Medical Research, Mill Hill, London, UK). All antigens were 
coupled to DNP as previously described (42). In one experiment, 
mice were injected subcutaneously  first with alum-precipitated  an- 
tigen and then with four daily injections  of sCD40-3' I on the upper 
surface of the front legs. The mice were bled at various times after 
immunization. Mice used for these experiments were BALB/c  and 
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and maintained under normal laboratory conditions in the Royal 
Postgraduate Medical School animal facility. 
Adoptive Transfers to Measure Memory Responses.  BALB/c  mice 
(IgH  ~ allotype) treated with soluble mCD40-huq,  gl or controls 
treated with hulgG1 during primary responses to DNP-OVA were 
left for 10 wk. At this time, spleen and peripheral lymph nodes 
were taken from these mice, suspensions made, and 2  x  106 or 
5  ￿  106 cells (see legend to Fig. 6) were injected intravenously 
into 5 Gy-irradiated C.B20 mice (IgH  b allotype), together with 
5  x  106 spleen cells from KLH-primed C.B20 mice. The mice 
were immunized with 10/zg i.v. of soluble DNP-KLH. Cell sus- 
pensions from mice treated similarly were pooled before reconsti- 
tution. Mice were bled at 7 and 14 d after this and the sera assayed 
for donor anti-DNP  antibodies. 
IL-3 Limiting Dilution Assays.  The frequency of OVA-specific 
T cells was measured using an assay almost exactly as described 
by Ronchese and Hausmann (43). The only differences  were that 
we used the PBC3 IL-3-dependent cell line (44), adding 50 cells 
to the wells after the plates were irradiated. After 24 h, a rescue 
dose of IL-3 was added (1% of IL-3 containing supernatant; 41) 
and  culture  continued  for  4-5-d  more,  with  [aH]thymidine 
(Amersham International, Amersham, Bucks, UK) added for the 
final 16 h. Frequencies were calculated from the regression curve 
as described (43), and results were presented as frequency per total 
splenic T cell population. 
Antibodies, Flow Cytometry, and lmmunohistology.  FITC-labeled 
anti-CD25 (3C7; reacting with the p55, low affinity  11.-2 receptor) 
was purchased from PharMingen (San Diego, CA). GKI.5 (anti- 
CD4) was obtained from the American Type Culture Collection 
and biotinylated using biotin-N-hydroxysuccinimide  ester (Calbio- 
chem-Novabiochem  Corp.); this was detected using streptavidin-PE 
(Southern Biotechnology Associates, Birmingham, AL). CD40-L 
expression was detected using biotinylated sCD40-3r  (a blocking 
step with 2% human serum was included and CD40-hu3,1-biotin 
was diluted in PBS containing 2% human serum to avoid  the pos- 
sibility of Fc binding). Otherwise, cells were stained in standard 
fashion and analyzed  on a flow cytometer (Epics XL; Coulter Corp., 
Hialeah, FL). For assessment of GC formation, 5-gin-thick frozen 
sections of spleen were acetone  fixed  and stained  with biotin-labeled 
peanut agglutinin  (PNA; Vector Labs, Peterborough, UK) and 
horseradish peroxidase-labeled  streptavidin  (Southern Biotechnology 
Associates). 
Determination of  Antibody Titers.  Microtiter ELISA plates (Dy- 
natech Laboratories, ChantiUy, VA) were coated with the test an- 
tigen (DNP-bovine serum antigen, KLH, or C5) at 10 I~g/ml and 
50 gl/well in carbonate/bicarbonate buffer, pH 9.5. Assays were 
carried out and antibody titers worked out as previously  described 
(42). Briefly, this involved doubling dilutions of serum, starting 
at 1 in 20. Curves of absorbance (at 405 nm) against serum dilu- 
tion were plotted. The antibody titer was calculated  as the reciprocal 
of the dilution that gave an absorbance of 30% of the maximum 
absorbance reading for that particular assay. The maximum was 
given by a standard hyperimmune serum. Secondary antiisotype 
antibodies used in these assays  were the following: alkaline phos- 
phatase conjugates of goat anti-mouse  IgG1, goat anti-mouse 
IgG2a, goat anti-mouse IgM, and streptavidin (all purchased from 
Southern  Biotechnology  Associates). Anti-IgH  ~ allotype anti- 
bodies RS3.1 (recognizes  Igh6a on IgM; 45) and Ig(4a)10.9 (other- 
wise known as 20.9.10, recognizes Igh4a on IgG1; 46) were kind 
gifts from Drs. R. Palacios  (Basal  Institute for Immunology, Basel, 
Switzerland) and L. A. Herzenberg (Stanford University Medical 
School, Stanford CA), respectively.  These were biotinylated for use 
and detected using streptavidin-alkaline  phosphatase. Plates were 
read on a Titertek Multiscan MklI ELISA plate reader (ICN Bio- 
medicals, Costa Mesa, CA) at 405 nm. 
The half-life of hulgG1 or sCD40-yl in the serum was mea- 
sured using the following ELISA: sheep anti-human IgG1 was 
coated onto wells at 10 gg/ml. After blocking and incubation of 
serial dilutions of test sera, sheep anti-human IgG1 conjugated to 
alkaline phosphatase (The Binding Site) was added. The amount 
of human IgG1 in the sera was calculated from a standard curve 
generated from an ELISA using a titration of a human IgG1 my- 
eloma protein (The Binding Site). Mouse antibody responses to 
the human Fcgl portion of the CD40-fusion protein were assayed 
by coating human IgG1 myeloma protein onto wells at 10 gg/ml, 
incubating the test sera, and detecting bound mouse Ig with a goat 
anti-mouse  Ig alkaline phosphatase conjugate absorbed against 
human Ig (Southern Biotechnology Associates). 
Results 
Soluble CD40-TI Inhibits T-dependent B Cell Proliferation In 
Vitro.  To ascertain whether the sCD40-3,1 would block the 
CD40-CD40 ligand interaction in vivo it was necessary to 
assess the capacity of the chimeric protein to inhibit the in- 
teraction in vitro.  To this end it was introduced into a T 
cell-dependent B cell proliferation assay. The sperm whale 
myoglobin-specific Thl clone 11.3.7 was stimulated overnight 
with PMA plus ionomycin. As shown in Fig. 1 A  this in- 
duced the expression  of the CD40-L. The ceils were then 
fixed with paraformaldehyde and washed. Coculture of these 
fixed activated T cells with high density, resting B cells in- 
duces  the B cells to proliferate (Fig.  1 B),  a response that 
is enhanced by the addition of IL-4 or anti-Ig (data not shown). 
Addition of sCD40-'yl to the cultures, at a concentration 
of 2.5 gg/ml, inhibited the proliferation by "~75%. This is 
in line with previous observations (6-8). 
In Vivo Administration of Soluble CD40-TI  during Primary 
Immune Responses.  DBA/2 mice were immunized with 50 
gg i.p. of alum-precipitated DNP-OVA and split into three 
groups. The first was injected intravenously on the day of 
immunization (day 1) and then every day until day 5 with 
100/zg of sCD40-yl; the second received 100/xg of purified 
human IgG1 with the same regimen (i.e., days 1-5); and the 
third received 100 #g sCD40-3,1  starting on day 4 and con- 
tinuing daily until day 8 after immunization. The rationale 
for these regimes was as follows:  treatment from days 1-5 
might be expected to influence the initiation of the antibody 
response whereas treatment from days 4-8 might affect the 
development of memory B cell populations in GC that first 
appear in the spleen at around day 7. The human IgG1 was 
used as a control for the potential effects of Fc receptor binding. 
We chose not to use a fusion protein that bound to another 
molecule on the T  cell surface as this could introduce un- 
known effects into the control group. 
Fig.  2, A  and B  shows the serum antibody response  of 
these three groups of mice to DNP-OVA in the IgG1 and 
IgM classes. The IgG1 response,  at day 7, was inhibited by 
80% in the group given sCD40-3,1 from days 1-5 when com- 
pared with the group treated with hulgG1 (percent inhibi- 
tion calculated from the means of the two groups). At day 
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Figure 1.  Soluble  CD40-3"1 stains  an ac- 
tivated  T cell  clone  and blocks  T-dependent 
B cell activation  in vitro. (,4) FACS  |  plot 
of the binding  of sCD40-3'l-biotin to the 
Thl done, 11.3.7, before  (solidline)  and 24 h 
after (dotted  line)  activation  with PMA plus 
ionomycin.  (/3) Inhibition  by sCD40-3,1 of 
B cell  proliferation  stimulated  by fixed,  ac- 
tivated Thl clone, 11.3.7, either alone  or 
together with IL-4. Although  not shown, 
note that addition of hulgG1 to the cul- 
tures had no inhibitory  effect on B cell 
proliferation. The mean _+ SD of  triplicate 
wells are shown. The experiment is repre- 
sentative of three such experiments. 
14 after immunization, these two groups show roughly equiva- 
lent responses.  Delaying the onset of sCD40-yl treatment 
had minimal effect on the anti-DNP response at day 7 or 
14 when compared with the control group. The IgM response 
in contrast  to  the IgG1  response was augmented by over 
fivefold in the mice treated with sCD40-'y1, in comparison 
with the hulgGl-treated animals (5.2-fold at day 7 and 4.2- 
fold at day 14). Again, delaying treatment until day 4 had 
only a marginal effect on the IgM response￿9 
It should be noted that the IgG1 isotype dominates the 
response of normal DBA/2 or BALB/c mice to DNP-OVA, 
as it is at least 10-fold higher than the IgM or the IgG2a 
response. However, the sCD40-3'l-induced inhibition is not 
restricted to the IgG1 subclass (Th2-type response) as we found 
similar reductions in the IgG2a subclass (data not shown for 
this experiment, but see Fig. 3 B). The response to the com- 
plement component, C5, was investigated because in normal 
DBA/2 mice there is a very strong antibody response that 
is restricted to the IgG1 subclass, with virtually no IgM pro- 
duced (DBA/2 mice are genetically deficient in C5, and there- 
fore respond to it as a foreign antigen; 47).  The responses 
to C5 in sCD40-'yl-treated mice are illustrated in Fig.  2, 
C and D. The IgG1 response of mice treated from days 1-5 
were inhibited by 79% at day 7 and by 51% at day 14, when 
compared with hulgGl-treated mice. Whereas the control 
group made a very poor IgM response to C5 (titer of 1 in 
13), the sCD40-yl-treated mice responded twofold better 
at day 7 and ll-fold better at day 14. 
The effects of sCD40-qH injections were fairly short-lived; 
to see if "suppression" could be prolonged we injected mice 
for the first 10 d of the response to DNP-OVA. Fig. 3, A-C 
shows that the inhibition of the IgG1 or IgG2a responses 
were maintained at least until day 14 in this experiment (IgG1, 
78% inhibition at day 7 and 61%  at day 14; IgG2a, 80% 
inhibition at day 7 and 72% at day 14). The increase in the 
IgM response was also maintained until day 14 (4.8-fold at 
day 7, 2.3-fold at day 14). Clearly the immunosuppression 
using sCD40-71 is maintained only as long as serum con- 
centrations do not fall below a critical level. 
sCD40-T1 Does Not Act by Removing Antigen-activated T 
Cells from the Lymphoid System.  In these experiments, we 
hope to study the effect of blocking the interaction of CD40 
on the B cell with its ligand on specifically activated T cells. 
The use of a chimeric protein containing the Fc portion of 
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administration  of  sCD40-3,1 on the 
primary  antibody  responses  to 
DNP-OVA and  C5.  Mice were 
treated with sCD40-~,I or hulgG1 
for the first 5 d of the response  or 
treated with sCD40-'y1 from  days 
4-8. Serum  responses  to DNP-OVA 
in IgG1 (A) and IgM (B) classes  and 
C5 in IgG1 (C) or IgM (/9) classes 
are shown. The results  are presented 
as the reciprocal  of  the dilution  that 
gave 30% of maximal binding (by 
standard sera), The mean and stan- 
dard deviation of titers from four 
to six mice per group are shown. 
The figures in brackets show the 
percent inhibition  or fold-augmen- 
tation  of the  sCD40-3,1-treated 
group compared  with the huIgG1- 
treated group. 
Ig in vivo could lead to the killing or removal of CD40- 
ligand-expressing T  cells by a number of means.  The first 
is by complement-mediated killing.  This was ruled out in 
these experiments because we used a strain of mice (DBA/2) 
that is deficient in C5 due to a widespread genetic defect in 
mouse populations (47), which prevents activation of the mem- 
brane attack complex (C6-9). However, there is still the pos- 
sibility of opsonization of cells either with complement or 
the Fc portion of the CD40 chimeric molecule. This may 
lead  to  removal  either  by  macrophages  or  to  antibody- 
dependent cell cytotoxicity. If activated T cells were removed 
in this way, the number of cells expressing activation markers 
other than CD40-L should also be depleted in mice injected 
with sCD40-3,1 after immunization. The peak of CD25 (IL-2 
receptor) expression is around days 2-3 after injection of alum- 
precipitated antigen (no Bordetella pertussis).  Given the rapid 
expression of CD40-L in vitro and the fact that the in vivo 
effects are only apparent if the sCD40-3,1 is given early in 
the response, we would expect CD40-L expression in vivo 
to be earlier than CD25.  Fig.  4 A  shows that the number 
of CD4 § T  cells that acquired CD25 during the course of 
the response was similar in sCD40-3,1-treated mice and in 
control mice. A second approach was to measure the frequency 
of antigen-specific T  cells in mice treated with sCD40-3,1. 
Fig.  4 B, a representation of data from a limiting dilution 
analysis of OVA-specific T  cells that produce IL-3 (i.e., both 
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an antibody  response  to DNP-OVA. Responses  to DNP in the IgG1, IgG2a, 
and IgM classes are measured. The results represent the mean and stan- 
dard deviation  of serum titers from six mice per group. For further details, 
see the legend to Fig. 2. 
Thl  and  Th2),  demonstrates  that  far from  a depletion  of 
antigen-specific cells in these mice,  the frequency seems to 
be slightly higher (mean frequency of 1 in 24,000 spleen cells 
as opposed to  1 in  36,000  in  control mice). 
Other considerations for the efficacy of sCD40-3'I in vivo 
include its half-life and the development of anti-human Fc"/1 
responses. Fig. 4 C  shows that although  a large fraction of 
the sCD40-3'I (as well as hulgG1) was cleared from the cir- 
culation within 24 h of a single injection, a level of 2/xg/ml 
was maintained  for several days.  However, higher levels (> 
10/~g/ml) were maintained  in experimental mice that were 
injected each day. A response to the human Fc3,1 was almost 
undetectable in mice injected for 5 d with sCD40-3'I, in con- 
trast  to  those given hulgG1  (Fig.  4  D). 
sCD40-T1 Has No Effect on Secondary Responses.  Normal 
mice,  immunized  2  mo  previously with  alum-precipitated 
KLH, were boosted with 10 gg of soluble DNP-KLH. Half 
of the mice were treated  for 5 d  with  sCD40-',/1  and half 
with hulgG1.  Fig. 5 A  shows that there was no appreciable 
difference between the IgG1 response to carrier,  KLH, in ei- 
ther group.  In the IgM anti-KLH response (Fig.  5 B) there 
was a trend  towards higher titers in the sCD40-'yl-treated 
mice, but this is not significant.  The response to the DNP 
hapten  is a primary B cell response in which T  cell help is 
not limiting  and is provided by memory T  cells.  Fig.  5 C 
shows that  this response is CD40-L-dependent  in that  the 
IgG1 anti-DNP titers were reduced by >50%  at both days 
7 and 14. In this experiment,  the enhancement  of the IgM 
titers was only modest  (1.4-fold at  day 7;  Fig.  5 D). 
sCD40-T1  Treatment Inhibits the Generation of Memory B 
Cells.  10  wk  after  treatment  of DNP-OVA-immunized 
BALB/c  mice  (Igh a)  for  5  or  10  d  with  sCD40-3'I  or 
hulgG1,  as described,  the mice were killed and spleen and 
peripheral  lymph nodes taken.  Cell suspensions from simi- 
larly treated mice were pooled. 5  x  106 cells were injected 
into lightly irradiated  C.B20 mice (IgH  b) together with  5 
x  106 cells from KLH-primed C.B20 mice. The mice were 
immunized  with DNP-KLH.  In this way we were able to 
measure the anti-DNP  memory B cell response and ensure 
that T cell help is not limiting. In the first experiment, shown 
in Fig. 6 A, mice treated during the first 5 d of the primary 
response exhibited a marked diminution in their memory re- 
sponse (i.e.,  donor  IgG1)  10 wk later.  This  was especially 
noticeable after transfer of spleen cells (62% inhibition; with 
lymph node cells 36% less than controls). Unexpectedly, cells 
from mice treated from days 4-8 of the primary response with 
sCD40-3,1 exhibit distinctly enhanced memory response (in- 
creased by 70% in the spleen cell transfer and 40% with the 
lymph node cells). This phenomenon was observed in all three 
experiments  of this  type that  we performed. 
In a similar experiment  to the one described, we looked 
at the development of memory in mice treated with sCD40- 
yl for the first 10 d of the primary response. It was thought 
that  a longer term treatment  might  have a more profound 
effect on the memory response as it would cover the time 
during which GC were developing.  Fig.  6, B and C  shows 
the donor-derived memory response of IgG1 and IgM classes. 
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cells are not  deleted in  sCD40- 
71-treated mice. (-4) Expression 
with time  after  immunization  of  the 
activation  marker  CD25 in sCD40- 
71- and hulgGl-treated  groups. (B) 
Frequency of antigen-specific, Ib 
3-secreting  T h cells  in sCD40-71- 
and hulgGl-treated mice as mea- 
sured by a limiting dilution assay. 
Each point represents  the value  ob- 
tained from one mouse. (C) Decay 
over  time  of sCD40~  and hulgG1 
molecules  in the serum  of  mice  after 
a single injection  of 100/~g. Mean 
and standard deviations of results 
from three mice are shown. (D) 
Anti-human IgG1 response  in mice 
injected  with sCD40-71 or hulgG1 
for 5 d. Serum was assayed when 
the mice were  bled 9 d later. Anti- 
body binding is represented  as the 
absorbanee value given by  the 
ELISA reader. Means and SD from 
10 such mice are shown. 
The impairment of the donor IgG1 response was slightly more 
profound than in the previous experiments (74% of the con- 
trol responses).  It  is  interesting  to  note that  a  small but 
significant donor-derived IgM response appeared early (by 
7 d) in the sCD40-71-treated mice but was  absent in  the 
control mice. Thus it appears that a small population of IgM- 
producing memory cells developed in the sCD40-71-treated 
mice which, under normal circumstances, is negligible and 
hard to detect (Fig.  6 C). It should be noted that this in no 
way compensates for the impairment in the IgG memory re- 
sponse. 
sCD40-71  Treatment Has No Effect on the Generation of  Ger- 
minal Centers.  Lymphoid tissues taken from mice treated with 
sCD40-71 or hulgG1 for the first 10 d of a response to DNP- 
OVA were sectioned and examined for the presence of GC 
by staining with PNA-biotin.  Fig.  7 shows that there was 
no appreciable difference in the number or size of the GC 
in either group. It was conceivable that as Th cells expanded 
towards the end of the first week of the response, the efficiency 
of CD40 blockade was decreased. To address  this we looked 
at the GC reaction in lymph nodes draining a site of footpad 
injection of  DNP-OVA as the reaction was accelerated in lymph 
nodes, and was apparent by days 4-5 (48). After immuniza- 
tion, the mice were injected daily with sCD40-71 or hulgG1 
into the front legs  (subcutaneously into the upper surface 
of the leg). Sections of these axillary and brachial lymph nodes 
at day 5 revealed no difference in the development of PNA- 
positive GC (data not shown) between the two groups. The 
assessment  of GC development was possible because we used 
mice that were bred and maintained, before use, under specific 
pathogen-free conditions. Such mice have no preexisting GC 
in the spleen. In addition, unimmunized mice housed in the 
same cages as the treated mice had no splenic GC (data not 
shown) and so we are confident that the GC reactions ob- 
served were elicited by the immunization. 
Discussion 
The available experimental evidence suggests the interac- 
tion of CD40 with CD40-L occurs at a variety of  levels during 
T-dependent B cell responses.  It is implicated in B cell acti- 
vation/proliferation (1-5,  16-18), in differentiation to anti- 
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effect  on a secondary  anti-KLH  re- 
sponse but inhibits  the primary  re- 
sponse to hapten on the same car- 
tier. Mice,  primed 8 wk previously 
with alum-precipitated  KLH were 
treated  with sCD40-34 or huIgG1 
for the 5 d after boosting of the 
mice with soluble  DNP-KLH.  Sec- 
ondary  serum  responses to KLH in 
IgG1 and IgM classes are shown 
in A and B, respectively,  whereas 
the primary  responses to DNP are 
shown in C (IgGl) and D (IgM). 
The results are  presented as  the 
reciprocal of the dilution  that gave 
30% of maximal  binding (by stan- 
dard sera). The mean  and standard 
deviation of titers from six mice 
per group are shown. The figures 
in brackets show the percent inhi- 
bition or fold-augmentation  of the 
sCD40-',/1-treated group  compared 
with the huIgGl-treated  group. 
body-secreting plasma  cells  (19-21),  in  isotype switching 
(26-29),  in rescue/selection  of ceUs in GC undergoing affinity 
maturation (36, 39), and in the generation of memory B cells 
(36,  39).  The aim of these experiments was to place  these 
multifarious observations into the context of  immune responses 
in vivo. Three major conclusions can be drawn from the results. 
(a)  Memory  B  cell  populations  do  not  develop  if  the 
CD40-CD40 ligand interaction is blocked even though GC 
development appears to be unaffected. This is one of the first 
direct demonstrations that CD40  signals  are necessary for 
the development of memory B cells. (b) T-dependent anti- 
body responses can proceed in the absence of CD40 ligation, 
albeit in a quantitatively and qualitatively inferior form. This 
has recently been the subject of some debate arising from 
the analysis of HIMG1 patients. (c) Ligation of CD40 is es- 
sential for the maturation of T-dependent antibody response 
to its full range ofisotypes, in agreement with many previous 
observations, not least HIMG1. The approach of blocking 
CD40 ligation at defined points of the immune response has 
clear advantages  over analysis of genetic mutants that lack 
functional CD40 ligand activity from birth. We can inves- 
tigate the levels of action of what appears to be a multifunc- 
tional  receptor-ligand  interaction,  avoiding  the  potential 
problem of an immune system that has undergone a dysfunc- 
tional development. For instance,  HIMG1 patients exhibit 
severely disorganized secondary lymphoid tissues in which 
normal cell interactions may be precluded (see below for fur- 
ther discussion). 
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memory B cell populations is im- 
paired in mice  treated  with sCD40- 
3"1. (.4) Donor IgG1 anti-DNP 
memory  responses  in adoptive  hosts 
of cells taken  from  mice treated 10 
wk previously  with sCD40-3,1 or 
hulgG1 for either days  0-5 or 4-8 
after priming. Cells from spleen 
or lymph  nodes  were assayed  sepa- 
rately. B and C show the donor 
IgG1 (B) or IgM (C) responses de- 
rived from cells taken from mice 
treated  with sCD40-~/1 or hulgG1 
for 10 d during  the primary  response 
10 wk previously. The mean and 
standard  deviation  of titers  from  five 
to six mice per group are shown. 
The figures in brackets show the 
percent inhibition  or fold-augmen- 
tation of  the  sCD40-3,1-treated 
group compared  with the hulgG1- 
treated group. 
CD40-L-dependent Pathway  for T-dependent B  Celt Activa- 
tion.  The most obvious conclusion to be drawn from these 
data is that, for the responses examined, blocking of the in- 
teraction of CD40 with its ligand on activated T  cells has 
profound consequences for both the quantity and quality of 
the primary antibody response.  Daily injections of sCD40- 
3,1 during the first 5 d after immunization abrogated, to a 
large degree, the predominant IgG1 response to a variety of 
antigens. Whereas the IgM response was augmented in com- 
parison with untreated mice, this in no way compensated 
for the loss of the IgG response.  With all of the antigens 
used, the IgG1 response was at least 10-fold higher than that 
of the IgM, however,  the enhancement of antigen-specific 
IgM observed in the sCD40-3,1-treated  mice was rarely greater 
than five-fold. Indeed, measurement of the total antigen- 
specific antibody production (in all classes) demonstrated a 
reduction in titer of at least twofold in all the experiments. 
Given the necessarily crude nature of the in vivo experiment, 
we cannot know with absolute certainty at which level of 
the response sCD40-3q has its effect. It may interfere with 
B  cell  activation and  proliferation,  isotype switching,  or 
differentiation to antibody-secreting cells. However, there are 
clues. That the increase in the antigen-specific  IgM response 
does not wholly compensate for the reduction in the IgG 
subclasses suggests the number of B cells activated or the 
burst size of the activated clones is smaller in sCD40-'yl-treated 
mice. If this were not true (i.e., if the clone sizes were similar), 
the amount of antigen-specific  antibody produced (irrespec- 
tive of class) should be the same in both sCD40-'yl-treated 
and control groups. This conclusion assumes  that there is 
no difference  in the rate at which either activated B cells 
differentiate into IgM or IgG-producing plasma cells or at 
which IgM or IgG plasma cells secrete antibodies (there is 
no evidence  to suggest this assumption is incorrect). This 
149  Gray et al. Figure 7.  GC develop  normally 
in sCD40-*/1-treated mice. Cryo- 
star sections of spleens from mice 
treated either with sCD40-'y1 (A) 
or hulgG1 (B) for 10 d after an in- 
terperitoneal injection of alum-pre- 
cipitated DNP-OVA; stained with 
biotin-labeled PNA that is highly 
expressed  on GC B cells  and revealed 
using horseradish  peroxidase-hbeled 
Streptavidin. Darkly stained GC are 
marked (G). xl00. 
argument places the "CD40 block" at an early point in the 
B-T cell interaction that leads to B cell activation and subse- 
quent proliferation.  The fact that  delaying the onset of ad- 
ministration of sCD40-'y1 had little or no effect on the specific 
immune  response  supports  this  analysis. 
There  are a number  of scenarios  that  might  explain  the 
inhibition  of isotype switching brought  about by a CD40 
block in these experiments or in hyper-IgM patients. (a) The 
simplest notion,  and one that fits with the conclusion that 
the CD40 block is at the earliest stage of B cell activation, 
is that isotype switching will not proceed in the absence of 
extensive cellular proliferation (49). (b) Alternatively, the li- 
gation of CD40 during B cell activation may initiate a cas- 
cade of signaling  events concluding with  the expression of 
lymphokine receptors, mediating signals that induce isotype 
switching  and  terminal  differentiation  (50).  The  fact  that 
resting  B  cells  express low levels  of IL-4 receptor  and  are 
responsive to the lymphokine when  delivered in combina- 
tion with an anti-Ig signal suggests that this proposition is 
not the whole story. (c) A variation on the second possibility 
is that the T cell requires the signal via CD40-1igand to pro- 
ceed to high rate lymphokine production.  The current  ex- 
periments  do  not  allow  us  to  distinguish  which  of these 
proposals is correct. 
CD40-independent Pathway of T-dependent B  Cell Activa- 
tion.  In these experiments and in hyper-IgM patients (26-29), 
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T-dependent antibody production. The "compensatory" IgM 
antibody response is T  cell dependent. IgM is often viewed 
as a relatively T-independent antibody class, in that responses 
to T independent antigens are restricted largely to this class, 
however, T cell help is required for the IgM responses to TD 
antigens.  The antigens used in this study do not elicit re- 
sponses in nude, athymic mice (Gray, D., personal observa- 
tion). Clearly, IgM responses to some antigens are T-depen- 
dent  and  patients  with  defective CD40-1igand  can  make 
responses to TD antigens (21, 31). Thus there is a pathway 
for T-dependent B cell activation that is independent of CD40- 
signaling.  There is some confusion in the recent literature 
on this point. Korth~uer et al. (26) report that the T-dependent 
PWM fails to induce IgM secretion from cells of HIGM1 
patients,  this only being possible  in the presence of cross- 
linking antibodies to CD40. This directly contradicts a number 
of older studies (32-34) in which cells from HIGM1 patients 
produced IgM in response to PWM.  It seems likely to us 
that a variety of signaling pathways are still open to B and 
T  cells in the absence of CD40-L  and that  these can lead 
to IgM secretion by the B cell (for a review, see reference 51). 
Not only do mice treated with sCD40-'rl  make specific 
IgM responses, they make super-normal responses. The sim- 
plest explanation for this is that cells which would normally 
be diverted into the "IgG arm" (CD40oL  dependent; Fig. 
8) of the response by ligation of their CD40 remain, instead, 
in the IgM arm. Thus, more Ag-specific precursors enter this 
pathway than would normally do so. As we have already dis- 
cussed, the fact that this hyper-IgM response does not wholly 
compensate for the loss of the IgG response may reflect the 
less intense clonal expansion in the IgM arm (CD40-L in- 
dependent) in comparison with the IgG arm (CD40-L de- 
pendent). 
Secondary responses also seem to be relatively CD40-L in- 
dependent. Treatment of mice with sCD40-'rl  during the 
5 d after a boost of KLH has little observable effect on the 
IgG antibody titers. It might be argued that the larger number 
of CD40-L-expressing,  antigen-specific Th cells present in 
the secondary response would mean that  the blockade of 
CD40-L would require larger doses of sCD40-'rl  than we 
used. This does not seem to be the case as in the very same 
mice a concomitant primary response to DNP helped by the 
same KLH-specific memory T  cells is inhibited by the dose 
of sCD40-3q  that we use. In other words preactivated or 
memory B  cells  do  not  rely upon  a  signal  via  CD40  to 
proliferate and produce antibody. This result is in contradic- 
tion to that recently published by Foyet al.  (52)  in which 
mice are treated with a hamster antibody to CD40-L. Indeed 
there are a number of points upon which there are discrepan- 
cies. Foy et al. (52) find profound and long-term inhibition 
of primary IgM and IgG responses and secondary responses. 
All of the effects that we observed are transient except for 
the impairment of memory development (see below). This 
might be explained by the longer half-life of their antibody, 
a higher affinity for the ligand than the natural receptor, higher 
doses used, or any combination of these. We suspect in addi- 
tion that such profound and long-term effects indicate a differ- 
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Figure 8.  Scheme  of  B cell  differentiation  illustrating  CD40-1igand-de- 
pendent and-independent  pathways.  Note that the CD40-b-independent 
pathway seems to include proliferation  in GC but may not involve the 
processes of somatic mutation and af~nity selection. 
ence in the mode of action between the anti-gp39 antibody 
and the soluble CD40-yl; i.e., anti-gp39 (MR-l) causes de- 
letion of T  cells that express CD40-L.  We have shown by 
limiting dilution analysis that the frequency of antigen-specific 
Th cells is not reduced in sCD40-3,1-treated mice. Foy et 
al. (52) have not made a frequency analysis but use an adop- 
tive transfer system to  show that T  cell populations  from 
treated mice can support a secondary type response in adop- 
tive hosts. There are two reasons to believe that this control 
will be inconclusive: First, they transfer a vast excess of primed 
cells (5  x  107). In our own experience of adoptive transfer 
assays of memory B cells, 5  x  106 cells is sufficient and op- 
timal if quantitation is required. A significant reduction in 
the frequency of antigen-specific T cells in MR-l-treated mice 
would go undetected in this experiment. Second, the popu- 
lation transferred to the adoptive hosts will contain T  cells 
that have already been activated but which, by day 7 before 
transfer, may not yet have expressed CD40-L. These will still 
be capable of supporting the B cell response in the adoptive 
host. 
Development of Memory  B  Cells Is  Impaired by  CD40-L 
Blockade.  Treatment of mice for even the first 5 d of a re- sponse with sCD40-'y1 caused a depression of the memory 
response (by ;>60%) 10 wk later. The impairment of memory 
development was increased to >70%  by treatment for the 
first 10 d of the response. The fact that the memory popula- 
tion does not recover with time, like the primary IgG1 anti- 
body response, suggests that the decision to enter the memory 
B cell pathway is made during the very early stages of the 
immune response. This notion is supported by the observa- 
tion that mice, in which the sCD40-y1 injections were delayed 
until day 4 of the primary response, develop normal and pos- 
sibly enhanced memory responses. There are,  at least, two 
ways to explain this phenomenon. First, a particular type of 
T  cell interaction, presumably involving CD40 ligation, is 
necessary at an early stage to allow the B cell to enter the 
memory pathway. The alternative is the proposal of Linton 
et al. (53) that preexisting in the animal is a population of 
memory precursor B cells that are preferentially utilized in 
memory responses and not in primary antibody production. 
If this is the case, the data presented here indicate that this 
memory precursor population is dependent upon CD40 sig- 
naling for clonal expansion. Whichever of these two alterna- 
tives is correct, it is clear that the IgM-producing/CD40-L 
independent arm  of the response does not  normally give 
rise to appreciable numbers of memory B cells. However, in 
sCD40-~/1-treated mice, a small but significant IgM memory 
response is revealed at day 7 which is undetectable in the control 
group. We should point out that we cannot conclude from 
these data  that  the CD40  signal  is  wholly sufficient for 
memory cell differentiation. Other signals may be required; 
we favor the idea that CD40 ligation induces a state of differen- 
tiation in which the cells can receive "survival" signals. 
In a number of experiments we have observed that  the 
memory populations in the spleen are more severely affected 
by sCD40-3q  treatment than populations  recovered from 
lymph nodes. In the responses examined the major part of 
the memory response seems to be derived from cells residing 
in the spleen. The responses from donor spleen cells are up 
to twofold higher than those achieved by transfer of a similar 
number of lymph node cells. A discrete population of memory 
cells is known to reside in the marginal zone of the spleen 
(54). These cells are not found in significant numbers in lymph 
nodes. Antigen-specific B cells settle in the marginal zone 
during the first week after immunization and remain there 
for several weeks as a pool of cells quite separate from the 
recirculating pool (marginal zone B cells are sessile; 54). Any 
bias of the response towards this splenic population may simply 
reflect the route of immunization (intraperitoneal), although 
clearly its development seems dependent upon an early CD40 
signal. The development of hapten-binding B cells in the mar- 
ginal zone of animals treated with sCD40-y1 is now under 
investigation. 
The Signal for Initiation of GC Proliferation Is Not Delivered 
via  CD40.  The central role of GC  in  the generation of 
memory B cells is well established (for a review see reference 
55). For this reason we were surprised to find that in sCD40- 
"yl-treated mice, there was no diminution of the GC reac- 
tion, either in size or in the number of loci. Even mice that 
made virtually no IgG response to the immunizing antigen 
(>90% inhibition) exhibited perfectly normal GC develop- 
ment. This might indicate that the concentration of sCD40- 
3'1 required for blocking of the IgG switch is insufficient 
to inhibit  GC development (because of differences in  the 
affinity or number of interactions necessary). We do not be- 
lieve that this is the case as neither prolonged injection of 
100/~g/mouse/d (for 10 d; Fig. 7) nor administration of 500 
#g/d over 8 d  (two mice, data not shown) had any effect 
on the appearance of GC. This result is in sharp contrast to 
the study of Foyet al.  (56), who show that injection of a 
hamster antibody to CD40-L ablates GC formation. In our 
minds the discrepancy is due to the different action of the 
two treatments. As we have previously discussed we suspect 
that the hamster antibody has its effects by deleting antigen- 
specific, activated T  cells. At face value,  these data also ap- 
pear to contradict the observation in HIMG1 patients that 
no GC develop, however, upon further examination, it may 
not be so unexpected. HIMG1 secondary lymphoid tissues 
show gross abnormalities that include a lack of B cell fol- 
licles (31). It may not be surprising that GC do not form 
in these people if the basic structures and accessory cells are 
missing. The signals  that initiate GC proliferation and the 
phenotypic changes associated  with GC B cells have been 
a matter of intense interest in this and several other laborato- 
ries for some time. We find that cross-linking of CD40 with 
CD40-L in vitro does not cause these changes (our unpub- 
lished data). 
Our preferred conclusion is that CD40 signals are not neces- 
sary for the initiation of proliferation of B cells in GC.  B 
cells  activated  via  CD40-L-dependent  or  -independent 
pathways are equally likely to enter and proliferate in GC. 
Under normal circumstances, the dominant GC population 
would consist of B cells activated in association with CD40- 
L-bearing T cells because of their greater frequency (arising 
from their greater proliferative activity; see above). Whereas 
entry into the GC differentiation pathway and proliferation 
in  GC  may be  CD40-L-independent,  CD40  signaling  is 
thought to play a role in the selection of cells within the 
GC,  as GC B cells in vitro can be rescued from apoptosis 
by antibodies to CD40 (36).  The product of that rescue is 
a small slg* lymphocyte, leading to the speculation that the 
CD40 signal induced memory cell differentiation. In one way 
the current data concur with this conclusion in that even 
though the GC reaction proceeds in sCD40-y1-treated mice, 
there is little generation of memory cells. On the other hand, 
the crucial CD40 signal may be delivered earlier, before entry 
into the GC. For instance, a regime of injections of sCD40- 
3'1 designed to coincide with the early phase of the GC reac- 
tion  (i.e.,  days 4-8)  has  no effect on the development of 
memory, in contrast to early onset of injections (days 0-5). 
Also, the most convincing study to date of the localization 
of CD40-L-expressing T cells in lymphoid tissues places them 
only in extra-follicular sites  (57) where primary activation 
is thought to occur (58).  These data are consistent with the 
notion that only CD40-1igated B cells have the capacity to 
be selected for re-entry into the recirculating pool and long- 
term survival as memory cells. 
In the context of events that are happening within the GC, 
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GC are easy to measure, the quality of the GC in sCD40- 
3~l-treated mice is more difficult to assess. We are currently 
looking for the presence of somatic mutations in cells from 
sCD40-qrl-treated mice and are measuring the affinity  of an- 
tibodies derived from these cells after fusion to generate hy- 
bridomas. The fact that cells in sCD40-3,1-treated mice ap- 
pear to proliferate in the GC but do not enter the "long-lived" 
memory pool might indicate that the ceils die in situ. Our 
preliminary analysis of apoptosis in GC cells from these mice 
indicates a three- to fivefold increase in cell death compared 
with the same populations from control mice (assessed by 
titration of GC B cells into a DNA fragmentation assay; data 
not shown). 
In conclusion, all of the data presented indicate that the 
most important site of action of CD40-L in T-dependent 
antibody responses  is during the earliest phases of B-T cell 
interaction. All of the downstream effects of the sCD40-q/1 
treatment, such as lack of isotype switching, antibody secre- 
tion, and memory cell formation can be accounted for by 
an early block. In addition, if the blockade is delayed by 4 d 
none of these lesions develops. Fig. 8 summarizes two pathways 
of B cell differentiation that can be defined based on a depen- 
dence on CD40-L. The CD40-L-independent pathway ap- 
pears to be a minor pathway under normal circumstances, 
however, it does have the potential (in these experiments or 
possibly with certain antigens) to generate T-dependent IgM 
responses and a small IgM memory response. By far the major 
pathway is CD40-L dependent, leading to the full range and 
volume of antibody production and to the vast majority of 
memory B cells. Irrespective of their interaction with CD40-L 
all B cells activated within a cognate T cell interaction seem 
capable of proliferating in GC. We are keen to know if the 
events of somatic mutation and affinity selection that occur 
in the GC can proceed normally in the absence  of CD40 
signals, either to initiate mutation or to mediate long-term 
survival  signals. 
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